risedronic acid has been researched along with Chronic Disease in 8 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| "We studied the bone resorption state in GC-treated CKD patients and the effects of bisphosphonate on S-NTX." | 1.33 | Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. ( Fujii, N; Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Moriyama, T; Nagasawa, Y; Okada, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdou, WM | 1 |
| Ganoub, NA | 1 |
| Geronikaki, A | 1 |
| Sabry, E | 1 |
| Kunchur, R | 1 |
| Need, A | 1 |
| Hughes, T | 1 |
| Goss, A | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Yurci, A | 1 |
| Kalkan, AO | 1 |
| Ozbakir, O | 1 |
| Karaman, A | 1 |
| Torun, E | 1 |
| Kula, M | 1 |
| Baskol, M | 1 |
| Gursoy, S | 1 |
| Yucesoy, M | 1 |
| Bayram, F | 1 |
| Konrat, C | 1 |
| Boutron, I | 1 |
| Trinquart, L | 1 |
| Auleley, GR | 1 |
| Ricordeau, P | 1 |
| Ravaud, P | 1 |
| Wright, SA | 1 |
| Millar, AM | 1 |
| Coward, SM | 1 |
| Finch, MB | 1 |
| Hamano, T | 2 |
| Fujii, N | 2 |
| Nagasawa, Y | 2 |
| Isaka, Y | 2 |
| Moriyama, T | 2 |
| Okada, N | 1 |
| Imai, E | 2 |
| Horio, M | 2 |
| Ito, T | 2 |
| Mikami, S | 1 |
| Hori, M | 1 |
3 trials available for risedronic acid and Chronic Disease
| Article | Year |
|---|---|
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co | 2009 |
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agen | 2011 |
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Drug Therapy, Combination | 2007 |
5 other studies available for risedronic acid and Chronic Disease
| Article | Year |
|---|---|
Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Bone Resorption; | 2008 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chronic Disease; Etidronic Acid; Fluorobenzenes; France | 2012 |
Chronic diffuse sclerosing osteomyelitis treated with risedronate.
Topics: Adult; Calcium Channel Blockers; Chronic Disease; Etidronic Acid; Female; Humans; Osteomyelitis; Pai | 2005 |
Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Bone Density; Bone Density | 2006 |